Elastase-3-A (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human CELA3A (Elastase-3-A, UniProt P09093) expressed in HEK293 cells. Suited for serine protease activity assays, inhibitor IC50 determination, and antibody validation alongside the matched TPB anti-CELA3A antibody.
Expression system
HEK293
Cat. #
REC-Elastase3A

In stock

SKU
REC-Elastase3A
$498.00

Target Overview

Elastase-3-A (CELA3A; UniProt P09093) is a 270-amino acid serine protease of the chymotrypsin-like elastase family, secreted principally by the exocrine pancreas. Despite its nomenclature, CELA3A displays only limited elastolytic activity; its predominant catalytic preference is for substrates with alanine at the P1 position, distinguishing it from the classical neutrophil elastase (NE/ELANE) and from the closely related family member CELA3B. This selectivity makes CELA3A a useful enzymatic tool for dissecting substrate specificity within the pancreatic serine protease family. This recombinant is produced in HEK293 mammalian expression cells, a system that supports native-like disulfide bond formation and glycosylation patterns relevant to the secreted, processed form of the enzyme — considerations directly relevant to catalytic competence, as highlighted by structural work on the related family member CELA3B (Kumar et al., 2026, PMID 41187819). The full 270-residue sequence of the human isoform is the basis for this construct; researchers should confirm the precise expressed domain (zymogen vs. active-chain) in the product datasheet. In a research context, this recombinant is used to generate activity baselines against synthetic fluorogenic or chromogenic substrates, to profile inhibitor potency in IC50 assays, and as a well-characterised positive control antigen for validating anti-CELA3A antibodies by Western blot or ELISA. Researchers using this recombinant for antibody validation can pair it with the matched Triple Point Biologics anti-CELA3A antibody (SKU: RP-Elastase3A), which has been validated for Western blot applications. The HEK293-expressed format is particularly relevant where glycan-dependent epitope recognition or native tertiary fold is required for reliable immunoreactivity data.

Background

CELA3A belongs to the S1 family of trypsin-fold serine proteases (clan PA) and is one of several elastase-related enzymes secreted as zymogens from pancreatic acinar cells. Upon transit to the small intestine, it is activated by tryptic cleavage of the propeptide, contributing to the luminal proteolytic environment that degrades dietary protein. Among the pancreatic chymotrypsin-like elastases, CELA3A is distinguished by its alanine-directed specificity and its comparatively low elastolytic rate against insoluble elastin — properties that have motivated substrate mapping studies aimed at defining its physiological cleavage targets more precisely. Within the broader CELA gene family, research interest has grown as individual members have been characterised biochemically. Recent work demonstrating that CELA1 retains genuine pancreatic elastase-like activity (Jamwal et al., 2026, PMID 41520764) underscores the importance of defining the individual catalytic profiles of each family member rather than treating them as functionally interchangeable, a point equally applicable to CELA3A. Parallel biochemical characterisation of CELA3B — the closest paralogue to CELA3A — showed that catalytic activity correlates with native monomeric folding and that N-glycosylation does not abolish enzymatic function (Kumar et al., 2026, PMID 41187819), providing a structural and biochemical reference frame directly relevant to interpreting CELA3A recombinant activity data. CELA3A has appeared in proteomic and transcriptomic discovery datasets. Plasma extracellular vesicle proteomics identified CELA3A among candidate protein biomarkers associated with disease progression in diabetic retinopathy (Li et al., 2025, PMID 41068253), illustrating its presence in extracellular compartments beyond the gut lumen and motivating research into its detection and quantification in biofluids. Co-expression network analyses across human tissues have further placed CELA3A within gene communities reflecting pancreatic exocrine function (Russell et al., 2023, PMID 37976327), providing transcriptomic context for tissue-specific expression studies. As a research reagent, recombinant CELA3A supports in vitro substrate cleavage studies, inhibitor potency measurements, and structural comparisons within the pancreatic serine protease family. It also serves as a defined positive-control antigen for antibody-based detection methods, where a well-characterised, mammalian-expressed protein is preferable to bacterially produced alternatives that may lack native fold or post-translational modifications. Triple Point Biologics has produced validated proteinase and inhibitor antibody reagents since 1994; this recombinant was developed to complement that existing antibody portfolio and to support experiments requiring a catalytically relevant protein standard.

Applications

  • Fluorogenic substrate activity assay (e.g., Ala-AMC or succinyl-Ala-Ala-Pro-Ala-AMC cleavage) to establish CELA3A baseline kinetics
  • Inhibitor IC50 determination against candidate serine protease inhibitors using chromogenic or fluorogenic substrates
  • Antibody validation positive control for Western blot — pairs directly with Triple Point Biologics anti-CELA3A antibody (SKU: RP-Elastase3A)
  • ELISA standard curve generation for quantification of CELA3A in biological samples
  • Substrate specificity profiling by positional scanning synthetic combinatorial library (PS-SCL) or mass spectrometry-based cleavage mapping
  • Comparative kinetic benchmarking against related pancreatic elastases (CELA1, CELA2A, CELA3B) in matched activity assays
  • Recombinant antigen for immunisation or hybridoma screening in the production of novel anti-CELA3A antibodies

References

  1. Jamwal D et al. Human CELA1 has pancreatic elastase-like activity. Biochimie. 2026. doi:10.1016/j.biochi.2026.01.004. PMID: 41520764.
  2. Kumar P et al. Catalytically active hCELA3B is a natively-folded monomer and is N-glycosylated. Protein Expr Purif. 2026. doi:10.1016/j.pep.2025.106840. PMID: 41187819.
  3. Li Z et al. Identification of plasma extracellular vesicle protein biomarkers in diabetic retinopathy progression. Sci Rep. 2025. doi:10.1038/s41598-025-19223-z. PMID: 41068253.
  4. Russell M et al. Gene communities in co-expression networks across different tissues. PLoS Comput Biol. 2023. doi:10.1371/journal.pcbi.1011616. PMID: 37976327.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Azurophilic granules; neutrophils; secreted on activation

Frequently Asked Questions

What is the expected molecular weight of recombinant CELA3A on SDS-PAGE and Western blot?

The full 270-amino acid sequence of CELA3A (UniProt P09093) predicts an unglycosylated molecular weight of approximately 29 kDa. Because this recombinant is produced in HEK293 cells, native-like glycosylation is retained, and the observed band on reducing SDS-PAGE typically migrates at 32–36 kDa. Under non-reducing conditions, intramolecular disulfide bonds may cause a slight upward shift. If you are running a Western blot positive control alongside RP-Elastase3A antibody, load the 32–36 kDa window as your reference.

What is the substrate specificity of CELA3A and how does it differ from neutrophil elastase?

CELA3A is a serine protease with a strong preference for alanine at the P1 position of its substrates, which makes it mechanistically distinct from neutrophil elastase (ELANE), whose primary P1 preference is valine or alanine on insoluble elastin matrices. CELA3A also differs from its closest paralog, CELA3B, in substrate selectivity. This P1-Ala preference means synthetic substrates such as Suc-Ala-Ala-Ala-pNA or Suc-Ala-Pro-Ala-pNA are appropriate for activity assays, while substrates optimized for ELANE (e.g., MeOSuc-AAPV-pNA) will underestimate CELA3A activity.

What activity assay substrate and buffer conditions work best for recombinant Elastase-3-A?

For chromogenic assays, Suc-Ala-Ala-Ala-pNA (3–5 mM final concentration) in 50 mM Tris-HCl pH 8.0, 150 mM NaCl provides a reliable baseline for CELA3A activity. The supplied storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is compatible with direct dilution into assay buffer; the glycerol concentration will be negligible at typical working dilutions of 1:10 or greater. Monitor absorbance at 405 nm. A starting enzyme concentration of 50–200 nM is recommended for kinetic runs, titrating downward if substrate turnover is too rapid within the linear range.

What starting concentration of recombinant CELA3A should I use for an inhibitor IC50 experiment?

For IC50 determinations, use CELA3A at a concentration at or below the apparent Km for your chosen substrate to ensure inhibitor potency is not underestimated (Cheng-Prusoff correction). With Suc-Ala-Ala-Ala-pNA, a starting enzyme concentration of 50–100 nM is practical with substrate at 0.5–1 mM. Include a vehicle control and confirm linear product accumulation over the assay window (typically 10–30 min at 37°C). Because this enzyme is supplied at >90% purity by SDS-PAGE, active-site titration with a serine protease inhibitor (e.g., PMSF titration) is recommended to determine the fraction of catalytically competent enzyme before IC50 calculations.

Can recombinant Elastase-3-A be used as a positive control for Western blot with the matched RP-Elastase3A antibody?

Yes — this is a primary validated use case. REC-Elastase3A and RP-Elastase3A are developed from the same target sequence in the same laboratory, making them a guaranteed matched pair for Western blot positive controls and antibody validation experiments. Load 20–50 ng of REC-Elastase3A per lane under reducing SDS-PAGE conditions; the RP-Elastase3A polyclonal antibody is validated for Western blot and should detect a clean band at 32–36 kDa. This pairing is particularly useful when validating RP-Elastase3A against pancreatic tissue lysates or cell lines with exocrine pancreatic lineage.

How much recombinant Elastase-3-A should I load as a Western blot positive control, and what band should I expect?

Load 20–50 ng of REC-Elastase3A per lane on a 12% SDS-PAGE gel under reducing conditions. Expect a primary band at 32–36 kDa, reflecting the glycosylated, processed form produced in HEK293 cells. A faint higher-molecular-weight smear is occasionally observed and is consistent with heterogeneous glycosylation, not degradation — purity is >90% by SDS-PAGE. If background is elevated with RP-Elastase3A antibody, titrate the antibody concentration down rather than increasing the recombinant load; excess antigen can paradoxically increase non-specific signal in polyclonal blotting systems.

How should recombinant Elastase-3-A be stored and handled to preserve activity after delivery?

REC-Elastase3A is shipped in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol in single-use aliquots. Upon receipt, store immediately at -20°C. Do not refreeze after thawing; plan your aliquot sizes around single experimental sessions. For dilutions below 10 nM (e.g., binding or low-end activity assays), supplement the working buffer with 0.1% BSA to prevent adsorptive loss on tube surfaces. The enzyme retains activity for at least 12 months at -20°C when freeze-thaw cycles are avoided. Avoid detergents above 0.01% Tween-20, which can disrupt the active site of serine proteases at low enzyme concentrations.

Is recombinant CELA3A expressed as a zymogen or active enzyme, and does it require activation before use?

CELA3A is secreted by the exocrine pancreas as a zymogen (pro-CELA3A) that requires tryptic cleavage for activation in vivo. The REC-Elastase3A recombinant is provided in its active, processed form — the propeptide has been removed during manufacturing, so no additional activation step is required before activity assays. The HEK293 expression system supports correct disulfide bond formation, which is essential for the structural integrity of the chymotrypsin fold and, by extension, catalytic competence. Confirm activity upon receipt using the Suc-Ala-Ala-Ala-pNA chromogenic assay before committing the protein to downstream experiments.

Validation imagery coming soon

Western blot validation figures for REC-Elastase3A will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →